# JS212 Combination Therapies in Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct07503756/  
OnCo record `nct07503756` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of capecitabine, bevacizumab (glioblastoma use) and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Shanghai Junshi Bioscience Co., Ltd., now recruiting.

## Summary

JS212 Combination Therapies in Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT07503756 by Shanghai Junshi Bioscience Co., Ltd., with a registry enrolment figure of 80 participants, started 2026-04-25 and due to reach its primary completion in 2027-12-30. Interventions recorded: JS212; Capecitabine; Bevacizumab; Oxaliplatin; JS207. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Investigator-assessed objective response rate (ORR); Safety and Tolerability(AEs); Safety and Tolerability(SAEs). Colorectal eligibility wording from the registry: "* Adults aged 18-75 years with histologically confirmed metastatic colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07503756
- Phase: 2
- Setting: An Open-label, Multicenter Phase 2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of JS212 Combination Therapies in Patients With Metastatic Colorectal Cancer
- Sponsor: Shanghai Junshi Bioscience Co., Ltd.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT07503756: https://clinicaltrials.gov/study/NCT07503756

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/)
- companies: [Shanghai Junshi Biosciences](https://onco.cc/companies/junshi/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07503756.json